0000950170-23-038741 | 6-K | XBRL Viewer | Newamsterdam Pharma Co NV

Print Document View Excel Document

Revenue - Summary of Revenue (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Total revenue	€ 9,562	€ 93,500
License Revenue \| License Performance Obligation
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Total revenue	5,000	€ 93,500
License Revenue \| R&D Performance Obligations
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Total revenue	€ 4,562

Share Capital and Share Premium	6 Months Ended
Jun. 30, 2023
Disclosure Of Classes Of Share Capital [Abstract]
Share Capital and Share Premium	Note 8 — Share Capital and Share Premium During the six months ended June 30, 2023, the Group issued 749,641 Ordinary Shares upon the exercise of Warrants and 14,910 Ordinary Shares upon the exercise of Company Options. The exercise of Warrants resulted in an increase of share capital and share premium of €90 thousand and €9.3 million, respectively. The exercise of Company Options resulted in an increase of share capital and share premium of €2 thousand and €138 thousand, respectively.

Share Capital and Share Premium

6 Months Ended

Jun. 30, 2023

Disclosure Of Classes Of Share Capital [Abstract]

Share Capital and Share Premium

Note 8 — Share Capital and Share Premium

During the six months ended June 30, 2023, the Group issued 749,641 Ordinary Shares upon the exercise of Warrants and 14,910 Ordinary Shares upon the exercise of Company Options. The exercise of Warrants resulted in an increase of share capital and share premium of €90 thousand and €9.3 million, respectively. The exercise of Company Options resulted in an increase of share capital and share premium of €2 thousand and €138 thousand, respectively.

Group Information	6 Months Ended
Jun. 30, 2023
Disclosure Of Group Information [Abstract]
Group Information	Note 1 — Group Information NewAmsterdam Pharma Company N.V. (the “Company” and together with its subsidiaries, the “Group”) is a global biotechnology company focused on the research and development of transformative therapies for cardio-metabolic diseases. The Company was incorporated in the Netherlands as a Dutch private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) under the name NewAmsterdam Pharma Company B.V. on June 10, 2022. On November 21, 2022, in connection with its merger with Frazier Life Sciences Acquisition Corp (“FLAC”), the Company’s corporate form was converted to a Dutch public limited liability company (naamloze vennootschap) and its name was changed to NewAmsterdam Pharma Company N.V. The Group’s principal place of business and registered office is Gooimeer 2-35, 1411 DC Naarden, The Netherlands. These unaudited condensed consolidated financial statements comprise the financial statements of the Group. Terms in these accompanying notes take on the same meaning as defined in the Company’s Annual Report on Form 20-F for the year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission on March 31, 2023 (the "Annual Report"), unless otherwise defined.

Group Information

6 Months Ended

Jun. 30, 2023

Disclosure Of Group Information [Abstract]

Group Information

Note 1 — Group Information

NewAmsterdam Pharma Company N.V. (the “Company” and together with its subsidiaries, the “Group”) is a global biotechnology company focused on the research and development of transformative therapies for cardio-metabolic diseases. The Company was incorporated in the Netherlands as a Dutch private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) under the name NewAmsterdam Pharma Company B.V. on June 10, 2022. On November 21, 2022, in connection with its merger with Frazier Life Sciences Acquisition Corp (“FLAC”), the Company’s corporate form was converted to a Dutch public limited liability company (naamloze vennootschap) and its name was changed to NewAmsterdam Pharma Company N.V. The Group’s principal place of business and registered office is Gooimeer 2-35, 1411 DC Naarden, The Netherlands. These unaudited condensed consolidated financial statements comprise the financial statements of the Group.

Terms in these accompanying notes take on the same meaning as defined in the Company’s Annual Report on Form 20-F for the year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission on March 31, 2023 (the "Annual Report"), unless otherwise defined.

Earnings Per Share - Additional Information (Details)		6 Months Ended
Earnings Per Share - Additional Information (Details)	Jun. 30, 2023 shares	Jun. 30, 2022 shares	Jan. 01, 2022 shares
Earnings per share [line items]
Exchange ratio		2.13
Number of potential ordinary shares excluded from calculation of anti-dilutive	17,983,485
Business Combination Agreement
Earnings per share [line items]
Number of shares exchanged		1,964,286	1,964,286
Number of shares issued upon exchange		4,185,360	4,185,360
Ordinary Shares \| Business Combination Agreement
Earnings per share [line items]
Number of shares exchanged		17,016,872
Number of shares issued upon exchange		36,258,312
Exchange ratio		2.13

Financial Risk Management - Summary of Maturity Profile of Group Financial Liabilities Based on Contractual Undiscounted Payments (Details) € in Thousands	Jun. 30, 2023 EUR (€)
Disclosure of Financial Risk Management [Line Items]
Trade and other payables	€ 17,903
Share based payment liabilities	2,951
Lease liability	87
Derivative warrant liabilities	7,727
Derivative earnout liability	7,553
Total financial liabilities	36,221
On demand [member]
Disclosure of Financial Risk Management [Line Items]
Share based payment liabilities	2,763
Derivative warrant liabilities	7,727
Total financial liabilities	10,490
Less than 3 months
Disclosure of Financial Risk Management [Line Items]
Trade and other payables	17,903
Share based payment liabilities	43
Lease liability	15
Total financial liabilities	17,961
3-12 months
Disclosure of Financial Risk Management [Line Items]
Share based payment liabilities	130
Lease liability	48
Total financial liabilities	178
More than 1 Year
Disclosure of Financial Risk Management [Line Items]
Share based payment liabilities	15
Lease liability	24
Derivative earnout liability	7,553
Total financial liabilities	€ 7,592

Segment Reporting - Additional Information (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of operating segments [line items]
Revenue	€ 9,562	€ 93,500
Menarini License
Disclosure of operating segments [line items]
Revenue	€ 9,600	€ 93,500

Revenue - Additional Information (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jan. 01, 2023	Dec. 31, 2022
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Long term prepaid expenses	€ 93		€ 146
Deferred revenue		€ 17,500
Deferred revenue recognized as revenue	4,600
Reduction in deferred revenue laibility	300
Research and Development Performance Obligation \| Menarini License
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Current liabilities	9,700
Non-current liabilities	€ 2,900

Trade and Other Payables - Schedule of Trade and Other Payables (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Trade And Other Current Payables [Abstract]
Share based payment liabilities	€ 2,951
Total trade and other payables	€ 20,854	€ 18,503

Earnings Per Share

6 Months Ended

Jun. 30, 2023

Earnings Per Share [Abstract]

Earnings Per Share

Note 10 — Earnings per Share

Earnings per share for the period presented has been determined by dividing the earnings attributable to shareholders by the weighted average number of shares outstanding during the period. NewAmsterdam Pharma’s former non-voting ordinary shares and voting ordinary shares are considered to be the same class of equity for purposes of determining the loss attributable per shareholder class per share.

In accordance with the Business Combination Agreement, 17,016,872 NewAmsterdam Pharma shares were exchanged for 36,258,312 Ordinary Shares following the internal reorganization, which reflects the exchange ratio of approximately 2.13. Consequently, the weighted average number of Ordinary Shares outstanding for basic and diluted EPS for the prior period has been restated as required by IFRS.


	June 30, 2022

Shares for basic EPS of NewAmsterdam Pharma - as reported		17,016,872
Shares for diluted EPS of NewAmsterdam Pharma - as reported		18,981,158
Exchange ratio		2.13
Shares for basic EPS of NewAmsterdam Pharma - restated		36,258,312
Shares for diluted EPS of NewAmsterdam Pharma - restated		40,443,670

In total, 1,964,286 NewAmsterdam Pharma Options were outstanding as of January 1, 2022 and as of June 30, 2022. At the time of the Exchange these were converted into 4,185,360 Company Options. The table below reflects the original and restated number of options in the diluted number of Ordinary shares, as appropriate.

The following table sets forth the computation of original and restated basic and diluted loss per share for the six months ended June 30:


(In thousands of Euro, except share and per share amounts)	2023			2022

(Loss) / profit for the period		(75,102	)		54,513
Weighted average basic number of Ordinary Shares - as reported		81,846,438			17,016,872
Weighted average diluted number of Ordinary Shares - as reported		81,846,438			18,981,158
Basic earnings per share - as reported		(0.92	)		3.20
Diluted earnings per share - as reported		(0.92	)		2.87
Weighted average basic number of Ordinary Shares - restated		81,846,438			36,258,312
Weighted average diluted number of Ordinary Shares - restated		81,846,438			40,443,670
Basic earnings per share - restated		(0.92	)		1.50
Diluted earnings per share - restated		(0.92	)		1.35

At June 30, 2023, outstanding share-based awards and unexercised Warrants were excluded from the calculation because their impact would be anti-dilutive. At June 30, 2023, the total number of potential Ordinary Shares excluded amounted to 17,983,485.

Related Parties - Additional Information (Details) € in Thousands	6 Months Ended
	Jun. 30, 2023 EUR (€)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 EUR (€)	Jun. 30, 2022 USD ($)
Disclosure of Transactions Between Related Parties [Line Items]
Share-based payment expenses \| $		$ 10,164		$ 290
Non-executive Directors
Disclosure of Transactions Between Related Parties [Line Items]
Cash remuneration received	€ 166		€ 39
Share-based payment expenses	€ 241		€ 11

Research and Development Expense (Tables)

6 Months Ended

Jun. 30, 2023

Analysis Of Income And Expense [Abstract]

Schedule of Research and Development Expense

Research and development expense consisted of the following items for the six months ended June 30:


	2023			2022

Clinical expenses		(44,256	)		(21,026	)
Non-clinical expenses		(1,837	)		(1,264	)
Personnel expense		(13,708	)		(1,869	)
Manufacturing costs		(12,633	)		(6,001	)
Regulatory expenses		(394	)		(381	)
Other R&D costs		(45	)		(47	)
Total research and development expenses		(72,873	)		(30,588	)

Selling, General and Administrative Expenses

6 Months Ended

Jun. 30, 2023

Selling General And Administrative Expense [Abstract]

Selling, General and Administrative Expenses

Note 5 — Selling, General and Administrative Expenses

Selling, general and administrative expenses consisted of the following items for the six months ended June 30:


	2023			2022

Included in selling expenses:
Commission expense		(160	)		(2,429	)
Included in general and administrative expenses:
Personnel expense		(4,737	)		(1,314	)
Travel costs		(370	)		(83	)
Intellectual property		(726	)		(699	)
Legal costs		(1,761	)		(2,250	)
Licenses		(9	)		-
Finance and administration		(3,702	)		(1,624	)
IT		(35	)		(10	)
Rent and office services		(95	)		(77	)
Marketing and communication		(381	)		(487	)
Insurance		(928	)		(8	)
Depreciation and amortization		(34	)		(36	)
Commercial costs		(611	)		—
Business development		(10	)		(132	)
Board fees		(157	)		(40	)
Miscellaneous		(20	)		(105	)
Total selling, general and administrative expenses		(13,736	)		(9,294	)

Share-Based Payments - Summary Of Number Of Options Outstanding and Weighted Average Exercise Price (Details)	6 Months Ended
	Jun. 30, 2023 shares € / shares	Jun. 30, 2023 shares $ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted average exercise price, Outstanding \| € / shares	€ 6.52
Weighted average exercise price, Granted \| $ / shares		$ 11.01
Weighted average exercise price, Exercised \| € / shares	6.89
Weighted average exercise price, Forfeited \| € / shares	9.96
Weighted average exercise price, Outstanding \| € / shares	€ 7.33
Number of options, Outstanding	11,146,861	11,146,861
Number of options, Granted	4,558,729	4,558,729
Number of options, Exercised	(14,910)	(14,910)
Number of options, Forfeited	(1,724,516)	(1,724,516)
Number of options, Outstanding	13,966,164	13,966,164
July 6, 2031
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted average exercise price, Outstanding \| € / shares	€ 1.16
Number of options, Outstanding	4,174,706	4,174,706
November 22, 2032
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted average exercise price, Outstanding \| $ / shares		$ 10.00
Number of options, Outstanding	6,140,444	6,140,444
January 1 - June 5, 2033
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options, Outstanding	3,651,014	3,651,014
January 1 - June 5, 2033 \| Minimum
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted average exercise price, Outstanding \| $ / shares		$ 10.90
January 1 - June 5, 2033 \| Maximum
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted average exercise price, Outstanding \| $ / shares		$ 13.85

Cash - Summary of Cash Comprise Entirely of Bank Balances (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Cash [abstract]
Total cash	€ 383,495	€ 438,522

Research and Development Expense

6 Months Ended

Jun. 30, 2023

Analysis Of Income And Expense [Abstract]

Research and Development Expense

Note 4 — Research and Development Expense

Research and development expense consisted of the following items for the six months ended June 30:


	2023			2022

Clinical expenses		(44,256	)		(21,026	)
Non-clinical expenses		(1,837	)		(1,264	)
Personnel expense		(13,708	)		(1,869	)
Manufacturing costs		(12,633	)		(6,001	)
Regulatory expenses		(394	)		(381	)
Other R&D costs		(45	)		(47	)
Total research and development expenses		(72,873	)		(30,588	)

Share-Based Payments - Summary of movements in the Number of Founder DRs Outstanding (Parenthetical) (Details)	6 Months Ended
	Jun. 30, 2022
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exchange ratio	2.13

Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure of operating segments [abstract]

Schedule of Breakdown of Group's Non-current Assets by Geographical Location

The following table shows the breakdown of the Group’s non-current assets (i.e., intangible assets, property, plant and equipment and long-term prepaid expenses) by geographical location as of:


	June 30, 2023		December 31, 2022
Non-current assets
Netherlands		81,640		83,172
USA		194		278
Total		81,834		83,450

Segment Reporting - Schedule of Breakdown of Group's Non-current Assets by Geographical Location (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Disclosure of operating segments [line items]
Total non-current assets	€ 81,834	€ 83,450
Netherlands
Disclosure of operating segments [line items]
Total non-current assets	81,640	83,172
USA
Disclosure of operating segments [line items]
Total non-current assets	€ 194	€ 278

Basis of Preparation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Disclosure Of Basis Of Presentation And Summary Of Significant Accounting Policies [Abstract]
Basis of Preparation and Summary of Significant Accounting Policies	Note 2 — Basis of Preparation and Summary of Material Accounting Policy Information Basis of Preparation These unaudited condensed consolidated financial statements as at June 30, 2023 and for the six months ended June 30, 2023 and 2022 should be read in conjunction with the Annual Report as the unaudited condensed consolidated financial statements are prepared on a condensed basis in accordance with IAS 34 Interim Financial Reporting and do not contain all information required for a complete set of financial statements prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). Unless stated otherwise, the unaudited condensed consolidated financial statements as at June 30, 2023 and for the six months ended June 30, 2023 and 2022 are presented on a basis consistent with the accounting policies set out in the Annual Report. There were no significant changes in accounting policies, critical accounting judgements and key sources of estimation uncertainty applied by us in these unaudited condensed consolidated financial statements compared to those used in the Annual Report. The unaudited condensed consolidated financial statements have been prepared on a historical cost basis, unless otherwise disclosed. The unaudited condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern, and which contemplates the recoverability of assets and the satisfaction of the liabilities and commitments in the normal course of business. Based on the Group’s current operating plan, management has assessed that the existing cash and cash equivalents will be sufficient to fund the Group’s anticipated level of operations for the twelve months following the date of the issuance of these financial statements. The functional currency of the Group has historically been EUR. In the first half of 2023, the Group reassessed its functional currency and determined the United States Dollar (“USD” or “$”) to be the Group’s functional currency beginning January 1, 2023. Significant elements involved in the determination of the functional currency change include a shift in the Group’s sources of financing from EUR to USD given its access to the U.S. public market and an increase of operating costs incurred in USD due to Phase III trials taking place predominantly in the United States, among other factors. Given these significant changes, management considered the economic factors outlined in IAS 21, The Effects of Changes in Foreign Exchange Rates and concluded that the majority of the factors supported the determination of the USD as the functional currency. The unaudited condensed consolidated financial statements are presented in Euro (“EUR” or “€”). In these notes, Euro amounts are presented in thousands, except for share and per share amounts and as otherwise indicated. The Company has elected to present its financial statements in EUR in order to provide information comparable to the historical financial information included within previous Company filings. New and Amended IFRS Standards that are Effective for the Current Year New standards and interpretations effective for the annual period beginning on January 1, 2023 did not have any material impact on the Company's condensed consolidated financial statements. New Standards, Interpretations and Amendments Issued but Not Yet Adopted by the Company At the date of authorization of these financial statements, the Group has not applied new and revised IFRS Standards that have been issued but are not yet effective. The amendments to the standards and interpretations presented are not expected to have a material impact on the consolidated financial statements in future periods.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - EUR (€)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities
Loss before tax	€ (75,102,000)	€ 54,513,000
Non-cash adjustments to reconcile loss before tax to net cash flows:
Depreciation and amortization	34,000	36,000
Finance income	(5,176,000)	(10,000)
Finance expense		5,000
Fair value change - derivative earnout and warrants	5,998,000
Foreign exchange gains	(2,770,000)	(1,070,000)
Share-based compensation	12,118,000	349,000
Changes in working capital:
Changes in trade receivables		(115,000,000)
Changes in prepayments and other receivables	3,686,000	(6,692,000)
Changes in trade and other payables	2,893,000	1,727,000
Changes in deferred revenue	(4,590,000)	21,500,000
Changes in non-current assets/liabilities
Changes in long-term prepaid expenses	51,000
Interest paid	(3,000)
Net cash provided by/(used in) operating activities	(62,861,000)	(44,642,000)
Investing activities
Purchase of equipment	(4,000)	(2,000)
Interest received	5,176,000
Net cash provided by/(used in) investing activities	5,172,000	(2,000)
Financing activities
Payments of lease liabilities	(30,000)	(33,000)
Net cash provided by financing activities	8,023,000	79,647,000
Net change in cash	(49,666,000)	35,003,000
Foreign exchange differences	(5,361,000)	1,383,000
Cash at the beginning of the year	438,522,000	53,092,000
Cash at the end of the year	383,495,000	89,478,000
Series A
Financing activities
Proceeds from issuing equity securities		€ 79,680,000
Exercise of Warrants
Financing activities
Proceeds from issuing equity securities	7,957,000
Exercise of Company Options
Financing activities
Proceeds from issuing equity securities	€ 96,000

Share-Based Payments - Summary of movements in the Number of Founder DRs Outstanding (Details)	6 Months Ended
	Jun. 30, 2023 shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Outstanding as at January 1	608,779
Granted/ purchased during the year	0
Outstanding as at December 31	608,779

Segment Reporting

6 Months Ended

Jun. 30, 2023

Disclosure of operating segments [abstract]

Segment Reporting

Note 12 — Segment Reporting

Operating segments are components of the Group that engage in business activities from which it may incur expenses, for which discrete financial information is available and whose operating results are evaluated regularly by the Company’s Chief Operating Decision Maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance. The activities of the Group are considered to be one segment which is reflected in its organizational structure and internal reporting and comprises the research, development and subsequent commercialization of innovative and proprietary compounds that have a potential therapeutic effect in cardiovascular disease. The Group does not distinguish in its internal reporting different segments, neither business nor geographical segments. The Chief Executive Officer is identified as the CODM and reviews the operating results regularly to make decisions about the resources and to assess overall performance of the Group.

Total revenues recognized from the Menarini License of €9.6 million and €93.5 million during the six months ended June 30, 2023 and 2022, respectively, are derived entirely from Italy.

The following table shows the breakdown of the Group’s non-current assets (i.e., intangible assets, property, plant and equipment and long-term prepaid expenses) by geographical location as of:


	June 30, 2023		December 31, 2022
Non-current assets
Netherlands		81,640		83,172
USA		194		278
Total		81,834		83,450

Earnings Per Share - Schedule Of Computation Of Original and Restated Basic And Diluted Loss Per Share (Details) - EUR (€)

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Earnings per share [line items]

(Loss) / profit for the period

€ (75,102)

€ 54,513

Weighted average basic number of Ordinary Shares

81,846,438

36,258,312

Weighted average diluted number of Ordinary Shares

81,846,438

40,443,670

Basic

^[1]

€ (0.92)

€ 1.50

Diluted

^[1]

€ (0.92)

€ 1.35

As reported

Earnings per share [line items]

Weighted average basic number of Ordinary Shares

81,846,438

17,016,872

Weighted average diluted number of Ordinary Shares

81,846,438

18,981,158

Basic

€ (0.92)

€ 3.20

Diluted

€ (0.92)

€ 2.87

[1]


(*)	Restated - see Note 10

Related Parties - Summary of Total Compensation Paid to KMPs (Details) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Transactions Between Related Parties [Abstract]
Short-term employee benefits	$ 2,198	$ 1,257
Share-based payments	10,164	290
Total compensation paid to key management personnel	$ 12,362	$ 1,547

Intangible Assets - Additional Information (Details)	Jun. 30, 2023 € / shares
Ordinary Shares
Disclosure of detailed information about intangible assets [line items]
Par value per share	€ 0.12

Selling, General and Administrative Expenses (Tables)

6 Months Ended

Jun. 30, 2023

Selling General And Administrative Expense [Abstract]

Schedule of Selling, General and Administrative Expenses

Selling, general and administrative expenses consisted of the following items for the six months ended June 30:


	2023			2022

Included in selling expenses:
Commission expense		(160	)		(2,429	)
Included in general and administrative expenses:
Personnel expense		(4,737	)		(1,314	)
Travel costs		(370	)		(83	)
Intellectual property		(726	)		(699	)
Legal costs		(1,761	)		(2,250	)
Licenses		(9	)		-
Finance and administration		(3,702	)		(1,624	)
IT		(35	)		(10	)
Rent and office services		(95	)		(77	)
Marketing and communication		(381	)		(487	)
Insurance		(928	)		(8	)
Depreciation and amortization		(34	)		(36	)
Commercial costs		(611	)		—
Business development		(10	)		(132	)
Board fees		(157	)		(40	)
Miscellaneous		(20	)		(105	)
Total selling, general and administrative expenses		(13,736	)		(9,294	)

Financial Risk Management

6 Months Ended

Jun. 30, 2023

Disclosure Of Financial Instruments [Abstract]

Financial Risk Management

Note 6 — Financial Risk Management

The Group’s risk management activities are the same as those disclosed in our Annual Report.

The table below summarizes the maturity profile of the Group’s financial liabilities based on contractual undiscounted payments. Payments related to foreign currency are included at the exchange rates applicable as at June 30, 2023.


			Less than		3 - 12		More than
	On demand		3 months		months		1 year		Total

As at June 30, 2023
Trade and other payables		—		17,903		—		—		17,903
Share based payment liabilities		2,763		43		130		15		2,951
Lease liability		—		15		48		24		87
Derivative warrant liabilities		7,727		—		—		—		7,727
Derivative earnout liability		—		—		—		7,553		7,553
Total financial liabilities		10,490		17,961		178		7,592		36,221

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (UNAUDITED) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Non-current assets
Intangible assets	€ 81,629	€ 83,160
Property, plant and equipment	112	144
Long term prepaid expenses	93	146
Total non-current assets	81,834	83,450
Current assets
Prepayments and other receivables	5,769	9,611
Cash	383,495	438,522
Total current assets	389,264	448,133
Total assets	471,098	531,583
Equity
Share capital	608,754	599,191
Other reserves	16,852	4,691
Translation differences	(8,879)
Accumulated loss	(194,463)	(119,361)
Total equity	422,264	484,521
Non-current liabilities
Deferred revenue	2,923	4,492
Lease liability	23	56
Derivative earnout liability	7,553	7,053
Total non-current liabilities	10,499	11,601
Current liabilities
Trade and other payables	20,854	18,503
Deferred revenue	9,690	13,008
Lease liability	64	62
Derivative warrant liabilities	7,727	3,888
Total current liabilities	38,335	35,461
Total equity and liabilities	€ 471,098	€ 531,583

Financial Risk Management - Additional Information (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Disclosure Of Financial Instruments [Abstract]
Derivative warrant liabilities	€ 7,727
Derivative earnout liability	7,553
Cash balance	€ 383,495	€ 438,522	€ 89,478	€ 53,092

Financial Risk Management (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure Of Financial Instruments [Abstract]

Summary of Maturity Profile of Group Financial Liabilities Based on Contractual Undiscounted Payments


			Less than		3 - 12		More than
	On demand		3 months		months		1 year		Total

As at June 30, 2023
Trade and other payables		—		17,903		—		—		17,903
Share based payment liabilities		2,763		43		130		15		2,951
Lease liability		—		15		48		24		87
Derivative warrant liabilities		7,727		—		—		—		7,727
Derivative earnout liability		—		—		—		7,553		7,553
Total financial liabilities		10,490		17,961		178		7,592		36,221

Share Capital and Share Premium - Additional Information (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) shares
Exercise of Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Increase in share capital	$ 90
Increase in share premium	9,300
Exercise of Company Options
Disclosure Of Classes Of Share Capital [Line Items]
Increase in share capital	2
Increase in share premium	$ 138
Ordinary Shares \| Exercise of Warrants
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares issued \| shares	749,641
Ordinary Shares \| Exercise of Company Options
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares issued \| shares	14,910

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Loss before tax	€ (75,102)	€ 54,513

Property, Plant and Equipment - Schedule of Movements in Property, Plant and Equipment, Net (Details) € in Thousands	Jun. 30, 2023 EUR (€)
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	€ 144
Ending balance	€ 112

FLAC Merger and Capital Reorganization - Additional Information (Details)	6 Months Ended
	Jun. 30, 2022 shares	Jun. 30, 2023 € / shares shares	Jan. 01, 2023 shares	Jan. 01, 2022 shares
Disclosure Of Business Combinations [Line Items]
Exchange ratio	2.13
Public Warrants
Disclosure Of Business Combinations [Line Items]
Number of warrants outstanding		3,850,321	4,600,000
Private Placement Warrants
Disclosure Of Business Combinations [Line Items]
Number of warrants outstanding		167,000	167,000
Business Combination Agreement
Disclosure Of Business Combinations [Line Items]
Number of shares exchanged	1,964,286			1,964,286
Number of shares issued upon exchange	4,185,360			4,185,360
Ordinary Shares
Disclosure Of Business Combinations [Line Items]
Par value per share \| € / shares		€ 0.12
Ordinary Shares \| Business Combination Agreement
Disclosure Of Business Combinations [Line Items]
Number of shares exchanged	17,016,872
Number of shares issued upon exchange	36,258,312
Exchange ratio	2.13

Earnings Per Share (Tables)

6 Months Ended

Jun. 30, 2023

Earnings Per Share [Abstract]

Summary Of Weighted Average Number Of Ordinary Shares Outstanding For Basic And Diluted EPS


	June 30, 2022

Shares for basic EPS of NewAmsterdam Pharma - as reported		17,016,872
Shares for diluted EPS of NewAmsterdam Pharma - as reported		18,981,158
Exchange ratio		2.13
Shares for basic EPS of NewAmsterdam Pharma - restated		36,258,312
Shares for diluted EPS of NewAmsterdam Pharma - restated		40,443,670

Schedule Of Computation Of Original and Restated Basic And Diluted Loss Per Share

The following table sets forth the computation of original and restated basic and diluted loss per share for the six months ended June 30:


(In thousands of Euro, except share and per share amounts)	2023			2022

(Loss) / profit for the period		(75,102	)		54,513
Weighted average basic number of Ordinary Shares - as reported		81,846,438			17,016,872
Weighted average diluted number of Ordinary Shares - as reported		81,846,438			18,981,158
Basic earnings per share - as reported		(0.92	)		3.20
Diluted earnings per share - as reported		(0.92	)		2.87
Weighted average basic number of Ordinary Shares - restated		81,846,438			36,258,312
Weighted average diluted number of Ordinary Shares - restated		81,846,438			40,443,670
Basic earnings per share - restated		(0.92	)		1.50
Diluted earnings per share - restated		(0.92	)		1.35

Selling, General and Administrative Expenses - Schedule of Selling, General and Administrative Expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Included in Selling Expenses [Abstract]
Commission expense	€ (160)	€ (2,429)
Included in General and Administrative Expenses [Abstract]
Personnel expenses	(4,737)	(1,314)
Travel costs	(370)	(83)
Intellectual property	(726)	(699)
Legal costs	(1,761)	(2,250)
Licenses	(9)
Finance and administration	(3,702)	(1,624)
IT	(35)	(10)
Rent and office services	(95)	(77)
Marketing and communication	(381)	(487)
Insurance	(928)	(8)
Depreciation and amortization	(34)	(36)
Commercial costs	(611)
Business development	(10)	(132)
Board fees	(157)	(40)
Miscellaneous	(20)	(105)
Total selling, general and administrative expenses	€ (13,736)	€ (9,294)

CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS (UNAUDITED) - EUR (€)
€ in Thousands

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Income Statement [Abstract]

Revenue

€ 9,562

€ 93,500

Research and development expenses

(72,873)

(30,588)

Selling, general and administrative expenses

(13,736)

(9,294)

Total operating expenses

(86,609)

(39,882)

Operating (loss) / profit

(77,047)

53,618

Finance income

5,176

Finance expense

(3)

(185)

Fair value change–earn out and warrants

(5,998)

Foreign exchange gains

2,770

1,070

(Loss) / profit before tax

(75,102)

54,513

(Loss) / profit for the period

€ (75,102)

€ 54,513

Earnings per share (in Euros)

Basic

^[1]

€ (0.92)

€ 1.50

Diluted

^[1]

€ (0.92)

€ 1.35

[1]


(*)	Restated - see Note 10

Financial Assets and Liabilities Fair Value

6 Months Ended

Jun. 30, 2023

Disclosure Of Financial Instruments [Abstract]

Financial Assets and Liabilities Fair Value

Note 7 — Financial Assets and Liabilities Fair Value

Financial liabilities consist of trade and other payables, lease liability, derivative warrant liabilities and derivative earnout liability.

The carrying amount of cash, trade and other payables approximate their fair value due to their short-term nature. The fair values of these financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. Lease liabilities are measured at amortized cost based on the present value of the contractual payments due to the lessor over the lease term.

Derivative Warrant Liabilities

At January 1, 2023 a total of 167,000 Private Placement Warrants and 4,600,000 Public Warrants (collectively, the “Warrants”) were outstanding. In the six months ended June 30, 2023, no new warrants were issued and 749,679 were exercised at a price of $11.50 per ordinary share, nominal value €0.12 per share, of the Company (the "Ordinary Shares"), for total proceeds of €8.0 million. At June 30, 2023, the Company had 3,850,321 and 167,000 Public Warrants and Private Placement Warrants outstanding, respectively.

The fair value of the outstanding Warrants increased from $0.87 per warrant as of December 31, 2022 to $2.09 per warrant at June 30, 2023. At the moment of exercise, the fair value of a Warrant is calculated as the difference between the exercise price and the closing price on the date of exercise of an Ordinary Share trading on Nasdaq under the ticker NAMS. For the six months ended June 30, 2023, the Group recognized a charge of €5.4 million in profit or loss, which has been presented as a change in the fair value of derivative warrant liabilities under fair value change – derivative earnout and warrants expense.

Derivative Earnout Liability

The Business Combination Agreement contemplates the issuance of Earnout Shares, totaling 1,886,137 Ordinary Shares, contingent upon the achievement of a development milestone. At December 31, 2022, 1,725,358 Earnout Shares were allocated to Participating Shareholders. During the period a Participating Optionholder forfeited their rights with respect to a total of 409 Earnout Shares. These shares were reallocated pro rata among the remaining pool of Earnout Shares. As a result, at June 30, 2023 an additional 374 Earnout Shares were allocated to Participating Shareholders for a total of 1,725,732 Earnout Shares.

At December 31, 2022, the fair value of the 1,725,358 Earnout Shares allocated to Participating Shareholders was €7.1 million. At June 30, 2023, the fair value of the 1,725,732 Earnout Shares allocated to Participating Shareholders was €7.6 million. The remeasurement of the financial liability resulted in a charge of €0.6 million in profit or loss, which has been presented as a change in the fair value of derivative warrant liabilities under fair value change – derivative earnout and warrants expense.

Fair value measurements

The financial liability for the derivative warrants is accounted for at fair value through profit or loss. The Public Warrants are considered liquid and are actively listed on Nasdaq and have been measured at fair value using the quoted price (Level 1).

The Private Placement Warrants have been measured at fair value using inputs other than quoted prices included in Level 1 that are observable for the liability (Level 2), since the terms of the Private Placement Warrants are considered to be nearly identical to the Public Warrants, and the Public Warrants have an observable price in the active market. For these reasons, the measurement of the Private Placement Warrants can be indirectly derived from the quoted price of the Public Warrants.

Based upon an assumed zero dividend rate and the fact that no strike price exists that would have led to any volatility measure relative to the Company’s share price, the fair value of the Earnout Shares allocated to Participating Shareholders resulting from the Black-Scholes pricing model is driven by the Company’s closing share price as a Level 1 input and the probability of milestone completion, estimated by management to be 40%, as a Level 3 input. As management’s judgment of the probability of milestone completion remained constant during the period, the change in fair value resulted from the Company’s price per share between the valuations performed at December 31, 2022 and at June 30, 2023. The resulting per share fair value of the Earnout Shares allocated to Participating Shareholders is €4.38 at June 30, 2023, compared to a per share fair value of €4.09 at the December 31, 2022.

The following table shows the carrying amounts of the financial liabilities measured at fair value through profit and loss on a recurring basis:


	Level 1		Level 2		Level 3		Total
Liabilities measured at FVTPL
Derivative warrant liability (Public Warrants)		7,406		—		—		7,406
Derivative warrant liability (Private Placement Warrants)		—		321		—		321
Derivative earnout liability		—		—		7,553		7,553
Total financial liabilities		7,406		321		7,553		15,280

Share-Based Payments - Summary Of Weighted Average Fair Value and Inputs Measurements Of Fair Value Equity Settled Options (Details)	6 Months Ended
	Jun. 30, 2023 EUR (€) yr € / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share value (EUR) \| € / shares	€ 10.31
Option exercise price (EUR) \| € / shares	€ 10.31
Dividend yield	0.00%
Fair value per option (EUR) \| €	€ 4.55
Minimum
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Volatility (%)	37.00%
Expected life (years) \| yr	5.3
Risk-free rate	3.55%
Maximum
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Volatility (%)	42.00%
Expected life (years) \| yr	7.0
Risk-free rate	3.98%

Lease - Schedule of Group's Lease Liabilitites (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Presentation Of Leases For Lessee [Abstract]
Lease liability	€ 64	€ 62
Lease liability	€ 23	€ 56

Basis of Preparation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Disclosure Of Basis Of Presentation And Summary Of Significant Accounting Policies [Abstract]
Basis of Preparation	Basis of Preparation These unaudited condensed consolidated financial statements as at June 30, 2023 and for the six months ended June 30, 2023 and 2022 should be read in conjunction with the Annual Report as the unaudited condensed consolidated financial statements are prepared on a condensed basis in accordance with IAS 34 Interim Financial Reporting and do not contain all information required for a complete set of financial statements prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). Unless stated otherwise, the unaudited condensed consolidated financial statements as at June 30, 2023 and for the six months ended June 30, 2023 and 2022 are presented on a basis consistent with the accounting policies set out in the Annual Report. There were no significant changes in accounting policies, critical accounting judgements and key sources of estimation uncertainty applied by us in these unaudited condensed consolidated financial statements compared to those used in the Annual Report. The unaudited condensed consolidated financial statements have been prepared on a historical cost basis, unless otherwise disclosed. The unaudited condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern, and which contemplates the recoverability of assets and the satisfaction of the liabilities and commitments in the normal course of business. Based on the Group’s current operating plan, management has assessed that the existing cash and cash equivalents will be sufficient to fund the Group’s anticipated level of operations for the twelve months following the date of the issuance of these financial statements. The functional currency of the Group has historically been EUR. In the first half of 2023, the Group reassessed its functional currency and determined the United States Dollar (“USD” or “$”) to be the Group’s functional currency beginning January 1, 2023. Significant elements involved in the determination of the functional currency change include a shift in the Group’s sources of financing from EUR to USD given its access to the U.S. public market and an increase of operating costs incurred in USD due to Phase III trials taking place predominantly in the United States, among other factors. Given these significant changes, management considered the economic factors outlined in IAS 21, The Effects of Changes in Foreign Exchange Rates and concluded that the majority of the factors supported the determination of the USD as the functional currency. The unaudited condensed consolidated financial statements are presented in Euro (“EUR” or “€”). In these notes, Euro amounts are presented in thousands, except for share and per share amounts and as otherwise indicated. The Company has elected to present its financial statements in EUR in order to provide information comparable to the historical financial information included within previous Company filings.
New and Amended IFRS Standards that are Effective for the Current Year	New and Amended IFRS Standards that are Effective for the Current Year New standards and interpretations effective for the annual period beginning on January 1, 2023 did not have any material impact on the Company's condensed consolidated financial statements.
New Standards, Interpretations and Amendments Issued But Not Yet Adopted by the Company	New Standards, Interpretations and Amendments Issued but Not Yet Adopted by the Company At the date of authorization of these financial statements, the Group has not applied new and revised IFRS Standards that have been issued but are not yet effective. The amendments to the standards and interpretations presented are not expected to have a material impact on the consolidated financial statements in future periods.

Events After the Reporting Period - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023 shares $ / shares
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Number of share options granted in share-based payment arrangement \| shares	4,558,729
Weighted average exercise price, Granted \| $ / shares	$ 11.01

Financial Assets and Liabilities Fair Value - Summary of Carrying amounts of Financial Liabilities Measured at Fair Value Through Profit and Loss (Details)	Jun. 30, 2023 EUR (€)
Disclosure of Financial Risk Management [Line Items]
Derivative warrant liabilities	€ 7,727,000
Derivative earnout liability	7,553,000
Recurring
Disclosure of Financial Risk Management [Line Items]
Derivative earnout liability	7,553
Total financial liabilities	15,280
Public Warrants \| Recurring
Disclosure of Financial Risk Management [Line Items]
Derivative warrant liabilities	7,406
Private Placement Warrants \| Recurring
Disclosure of Financial Risk Management [Line Items]
Derivative warrant liabilities	321
Level 1 \| Recurring
Disclosure of Financial Risk Management [Line Items]
Total financial liabilities	7,406
Level 1 \| Public Warrants \| Recurring
Disclosure of Financial Risk Management [Line Items]
Derivative warrant liabilities	7,406
Level 2 \| Recurring
Disclosure of Financial Risk Management [Line Items]
Total financial liabilities	321
Level 2 \| Private Placement Warrants \| Recurring
Disclosure of Financial Risk Management [Line Items]
Derivative warrant liabilities	321
Level 3 \| Recurring
Disclosure of Financial Risk Management [Line Items]
Derivative earnout liability	7,553
Total financial liabilities	€ 7,553

Related Parties (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure Of Transactions Between Related Parties [Abstract]

Summary of Total Compensation Paid to KMPs

The following table sets forth the total compensation paid to KMPs during the six months ended June 30:


	2023		2022

Short-term employee benefits		2,198		1,257
Share-based payments		10,164		290
Total compensation paid to key management personnel		12,362		1,547

Financial Assets and Liabilities Fair Value - Additional Information (Details) € / shares in Units, € in Millions			6 Months Ended		12 Months Ended
	Jan. 01, 2023 EUR (€) shares	Nov. 22, 2022 shares	Jun. 30, 2023 EUR (€) € / shares shares	Jun. 30, 2023 € / shares $ / shares shares	Dec. 31, 2022 EUR (€) € / shares shares	Jun. 30, 2023 $ / shares shares	Dec. 31, 2022 $ / shares
Disclosure Of Financial Instruments [Line Items]
Proceeds from exercise of warrants \| €	€ 8.0
Warrant exercise price per ordinary share \| $ / shares				$ 11.50
Fair value of warrants per warrant \| $ / shares						$ 2.09	$ 0.87
Fair value of earnout shares \| €			€ 7.6		€ 7.1
Fair value of earnout price per share \| € / shares			€ 4.38	$ 4.38	€ 4.09
Dividend Yield
Disclosure Of Financial Instruments [Line Items]
Anticipated dividend rate			0	0		0
Level 3
Disclosure Of Financial Instruments [Line Items]
Estimated probability percentage of milestone completion by management			40.00%
Ordinary Shares
Disclosure Of Financial Instruments [Line Items]
Number of warrants issued			0	0		0
Number of warrant exercised			749,679	749,679		749,679
Par value per share \| € / shares			€ 0.12	$ 0.12
Issuance of earnout shares		1,886,137
Earnout shares allocated to participating shareholders			1,725,732		1,725,358
Number of earnout shares forfeited					409
Additional earnout shares allocated to participating shareholders			374
Public Warrants
Disclosure Of Financial Instruments [Line Items]
Number of warrants outstanding	4,600,000		3,850,321	3,850,321		3,850,321
Private Placement Warrants
Disclosure Of Financial Instruments [Line Items]
Number of warrants outstanding	167,000		167,000	167,000		167,000
Warrant
Disclosure Of Financial Instruments [Line Items]
Charge recognized in profit or loss \| €			€ 5.4
Earnout Shares
Disclosure Of Financial Instruments [Line Items]
Charge recognized in profit or loss \| €			€ 0.6

Share-Based Payments

6 Months Ended

Jun. 30, 2023

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]

Share-Based Payments

Note 9 — Share-Based Payments

The Company has three Share-based payment plans and one restricted share award in place as at June 30, 2023:

•

The Company’s Long-Term Incentive Plan (the “Plan”);

•

The Company’s Supplementary Long-Term Incentive Plan (the “Supplementary Plan”);

•

the Company’s Rollover Option Plan (the “Rollover Plan,” together with the Plan and the Supplementary Plan, the “Plans”); and

•

Chief Executive Officer Restricted Share Award.

Long Term Incentive Plans

The Plans are equity-settled, and the Company may grant various forms of equity awards, including the granting of options to purchase Ordinary Shares (“Company Options”) and restricted stock units (“RSUs”), pursuant to the Plans.

The contractual term is 10 years from grant date for options granted under the Plans In general, each Company Option granted in 2023 has a four-year vesting period with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the next following three years.

The changes for the six months ended June 30, 2023 in the number of options outstanding related to Ordinary Shares and their related weighted average exercise prices are as follows:


			2023
	Weighted average exercise price		Number of options
Outstanding as at January 1	€	6.52		11,146,861
Granted during the year	$	11.01		4,558,729
Exercised during the year	€	6.89		(14,910	)
Forfeited during the year	€	9.96		(1,724,516	)
Outstanding as at June 30	€	7.33		13,966,164

As at June 30, 2023, 4,189,605 of the outstanding Company Options are exercisable. The options outstanding as of June 30, 2023 have a weighted average remaining contractual life of 9.0 years.


				2023
Expiry date	Exercise Price			Number of options
July 6, 2031	€		1.16		4,174,706
November 22, 2032	$		10.00		6,140,444
January 1 - June 5, 2033	$	10.90 - 13.85			3,651,014
Outstanding as at June 30	€		7.33		13,966,164

Fair Value of Options Granted

The Black-Scholes option pricing formula has been applied for measuring the fair value of the options granted. The weighted average fair values and the inputs (ranges) used in the measurement of the fair values of these equity-settled options at the date of grant are summarized below:


	2023
Share value (EUR)		10.31
Option exercise price (EUR)		10.31
Volatility (%)	37% - 42%
Expected life (years)	5.3 - 7.0
Dividend yield		0	%
Risk-free rate	3.55% - 3.98%
Fair value per option (EUR)		4.55

The expected option life is based on management’s best estimate of when the options will be exercised. Expected volatility is estimated by considering historical average share price volatility of a group of comparable companies over a period before the grant date being equal to the expected option life. The expected dividend rate is zero as the Company currently has no history or expectation of declaring dividends on its ordinary shares. The risk-free interest rate is based upon the U.S. Treasury yield curve in effect at the time of grant, with a term that approximates the expected life of the option.

Share-Based Payment Expenses Recognized for Options Granted

The fair value of the options is expensed over the relevant vesting periods using the graded vesting method, based on management’s estimate of the number of options that will eventually vest. For the six months ended June 30, 2023 and 2022, the total share-based payment expense recognized for the equity-settled options amounted to €12.1 million and €0.3 million, respectively.

In addition, during the six months ended June 30, 2023 and 2022, the Group recognized €1.1 million and €0.0million, respectively, as expenses for the employer social security contributions expected to be payable related to these options. The corresponding liability as at June 30, 2023 and December 31, 2022 amounts to €2.8 million and €0.1 million, respectively.

Restricted Stock Units (“RSUs”)

As at June 30, 2023 the Company had allocated 160,404 Earnout Shares to be granted to participants in the Plan who were directors, officers, employees or consultants of NAP B.V. as of the date of the Business Combination Agreement and who are at the time of the achievement of such milestone providing services to the Company or its subsidiaries ("Participating Optionholders") if and when a certain clinical development milestone is achieved during the earnout period. These Earnout Shares will be delivered in the form of awards of RSUs granted pursuant to the Plan to such Participating Optionholders who are at the time of achievement of such milestone still providing services to the Group.

The development milestone consists of the achievement and public announcement of Positive Phase 3 Data for each of the Company’s BROADWAY clinical trial and BROOKLYN clinical trial at any time during the period beginning on November 22, 2022 and ending on the date that is five years after such date.

There is no impact on these financial statements with respect to these RSUs due to the uncertainty of achieving the clinical development milestone.

Chief Executive Officer Restricted Share Award

In July 2021, our chief executive officer, Michael Davidson, M.D., paid the fair market value of the underlying ordinary shares (in aggregate €708,571) when he made an investment in restricted shares issued through Depositary Receipts as previously disclosed. Accordingly, the total fair value of these equity-settled share-based payment awards amounts to nil and there will be no expenses recognized in the income statement. This award had a four year vesting period with 25% vesting on August 1, 2021 and the remaining 75% vesting in equal monthly installments over the following three years.

In connection with the award arrangement, if Dr. Davidson leaves the Group, all unvested Ordinary Shares will be cancelled against payment by the Company to him of the lower of the (i) the purchase price paid and (ii) the fair market value of such Ordinary Shares at the time of forfeiture. In order to reflect the consideration paid and the possibility that the Ordinary Shares would be repurchased if Dr. Davidson becomes a "Good Leaver" (as such term is defined in the award agreement) during the vesting period, the Company has recognized the consideration as a financial liability until the award has fully vested, at which time it will be reclassified to equity provided that Dr. Davidson remains with the Group. This liability is measured at the lower of (i) the purchase price paid and (ii) the fair market value of the Ordinary Shares at the end of the reporting period. The liability for unvested Ordinary Shares as at June 30, 2023 amounted to €192 thousand.

For the six months ended June 30, 2023, the movements in the number of Ordinary Shares outstanding are as follows:


	2023
	Number of Ordinary Shares
Outstanding as at January 1		608,779
Granted/purchased during the year		—
Outstanding as at June 30		608,779

As of June 30, 2023, a total of 443,901 Ordinary Shares had vested.

Financial Assets and Liabilities Fair Value - Schedule of Inputs to Fair Value of Derivative Earnout Liability (Details)	Jun. 30, 2023
Dividend Yield
Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]
Inputs to fair value of derivative earnout liability	0

Current Prepayments and Other Receivables (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Prepayments
Total prepayments and other receivables	€ 5,769	€ 9,611

Revenue

6 Months Ended

Jun. 30, 2023

Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Abstract]

Revenue

Note 3 — Revenue

The Group earns revenue through a license agreement with A. Menarini International Licensing S.A. (“Menarini”) (the “Menarini License”), pursuant to which it granted Menarini an exclusive, royalty-bearing, sublicensable license under certain of its intellectual property and its regulatory documentation to undertake post approval development activities and commercialize multiple brands of obicetrapib. The Menarini License includes a non-refundable upfront payment, fixed reimbursements for the Group’s continued development costs, payments based upon the achievement of defined development, regulatory and commercial milestones, sales-based royalties, and certain cost sharing payments made by Menarini to the Group and by the Group to Menarini.

In January 2023, the Group achieved a clinical milestone related to our Phase 2 ROSE2 clinical trial which resulted in a €5 million milestone payment from Menarini in April 2023. Revenues related to the achievement of milestones under the Menarini License are attributed to the license performance obligation.

Revenue consisted of the following for the six months ended June 30:


	2023		2022
License revenue attributed from license performance obligation		5,000		93,500
License revenue attributed from R&D performance obligation		4,562		—
Total revenue		9,562		93,500

At January 1, 2023, the Group had total deferred revenue of €17.5 million. During the six months ended June 30, 2023, €4.6 million of the deferred revenue was recognized as revenue and a translation difference of approximately €0.3 million further reduced the deferred revenue liability. No additional deferred revenue was recognized during the period. The deferred revenue has been recognized within current and non-current liabilities based on the expected timing of the associated research and development services. In connection with the Menarini License, €9.7 million is recognized within current liabilities as the Company expects to perform the associated services within twelve months after the reporting period and the remaining €2.9 million is recognized within non-current liabilities as of June 30, 2023.

Revenue (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Abstract]

Summary of Revenue

Revenue consisted of the following for the six months ended June 30:


	2023		2022
License revenue attributed from license performance obligation		5,000		93,500
License revenue attributed from R&D performance obligation		4,562		—
Total revenue		9,562		93,500

Share Listing Expense - Additional Information (Details) - EUR (€) € in Thousands	Jun. 30, 2023	Dec. 31, 2022
Share Listing Expense [Line Items]
Fair value of issued shares	€ 608,754	€ 599,191

Events After the Reporting Period

6 Months Ended

Jun. 30, 2023

Disclosure Of Nonadjusting Events After Reporting Period [Abstract]

Events After the Reporting Period

Note 13 — Events After the Reporting Period

The Group evaluated all events through August 3, 2023 and determined that there were no reportable subsequent events to be disclosed or adjusted in the undaudited condensed consolidated financial statements.

Share-Based Payments (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]

Summary Of Changes In Number Of Options Outstanding And Weighted Average Exercise Prices

The changes for the six months ended June 30, 2023 in the number of options outstanding related to Ordinary Shares and their related weighted average exercise prices are as follows:


			2023
	Weighted average exercise price		Number of options
Outstanding as at January 1	€	6.52		11,146,861
Granted during the year	$	11.01		4,558,729
Exercised during the year	€	6.89		(14,910	)
Forfeited during the year	€	9.96		(1,724,516	)
Outstanding as at June 30	€	7.33		13,966,164


				2023
Expiry date	Exercise Price			Number of options
July 6, 2031	€		1.16		4,174,706
November 22, 2032	$		10.00		6,140,444
January 1 - June 5, 2033	$	10.90 - 13.85			3,651,014
Outstanding as at June 30	€		7.33		13,966,164

Summary Of Weighted Average Fair Value And Inputs Measurements Of Fair Value Equity Settled Option

The weighted average fair values and the inputs (ranges) used in the measurement of the fair values of these equity-settled options at the date of grant are summarized below:


	2023
Share value (EUR)		10.31
Option exercise price (EUR)		10.31
Volatility (%)	37% - 42%
Expected life (years)	5.3 - 7.0
Dividend yield		0	%
Risk-free rate	3.55% - 3.98%
Fair value per option (EUR)		4.55

Summary Of Share Based Payments Outstanding

For the six months ended June 30, 2023, the movements in the number of Ordinary Shares outstanding are as follows:


	2023
	Number of Ordinary Shares
Outstanding as at January 1		608,779
Granted/purchased during the year		—
Outstanding as at June 30		608,779

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) - EUR (€) € in Thousands	Total	Series A Tranche I I	Issued capital [member]	Issued capital [member] Series A Tranche I I	Share premium [member]	Share premium [member] Series A Tranche I I	Other reserves [member]	Translation differences	Retained earnings [member]
Opening balance at Dec. 31, 2021	€ 49,791		€ 113		€ 83,763		€ 591		€ (34,676)
Equity contribution		€ 79,680		€ 57		€ 79,623
Share based compensation	438						438
(Loss) / profit for the period	54,513								54,513
Total comprehensive (loss) / profit for the period	54,513								54,513
Ending balance at Jun. 30, 2022	184,422		170		163,386		1,029		19,837
Opening balance at Dec. 31, 2022	484,521		9,787		589,404		4,691		(119,361)
Exercise of Warrants	9,423		90		9,333
Exercise of Company Options	96		2		138		(44)
Share based compensation	12,205						12,205
(Loss) / profit for the period	(75,102)								(75,102)
Other comprehensive (loss) / profit for the period	(8,879)							€ (8,879)
Total comprehensive (loss) / profit for the period	(83,981)							(8,879)	(75,102)
Ending balance at Jun. 30, 2023	€ 422,264		€ 9,879		€ 598,875		€ 16,852	€ (8,879)	€ (194,463)

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2022-03-24
-Paragraph 18
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2022-03-24
-Paragraph 32
-Subparagraph a
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2022-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2022-03-24
-Paragraph 24
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2022-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 28
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2022-03-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2022-03-24
-Paragraph 39L
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2022-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 23
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard
-URIDate 2022-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2022-03-24
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2022-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2023-01-01
-Name IFRS
-Number 17
-IssueDate 2022-03-24
-Paragraph 113
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2022-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 81A
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2022-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 106
-Subparagraph d
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2022-03-24

+ Details

Financial Assets and Liabilities Fair Value (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure Of Financial Instruments [Abstract]

Summary of Carrying amounts of Financial Liabilities Measured at Fair Value Through Profit and Loss

The following table shows the carrying amounts of the financial liabilities measured at fair value through profit and loss on a recurring basis:


	Level 1		Level 2		Level 3		Total
Liabilities measured at FVTPL
Derivative warrant liability (Public Warrants)		7,406		—		—		7,406
Derivative warrant liability (Private Placement Warrants)		—		321		—		321
Derivative earnout liability		—		—		7,553		7,553
Total financial liabilities		7,406		321		7,553		15,280

Cover	6 Months Ended
Cover	Jun. 30, 2023
Document Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Registrant Name	NewAmsterdam Pharma Company N.V.
Entity Central Index Key	0001936258
Current Fiscal Year End Date	--12-31
Entity File Number	001-41562
Entity Address, Address Line One	Gooimeer 2-35
Entity Address, City or Town	Naarden
Entity Address, Postal Zip Code	1411 DC
Entity Address, Country	NL

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE PROFIT OR LOSS (UNAUDITED) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Statement of comprehensive income [abstract]
(Loss) / profit for the period	€ (75,102)	€ 54,513
Items that may be reclassified subsequently to profit or loss:
Translation differences	(8,879)	0
Other comprehensive (loss) / profit for the period, net of tax	(8,879)
Total comprehensive (loss) / profit for the period, net of tax	€ (83,981)	€ 54,513

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

+ Details

Research and Development Expense - Schedule of Research and Development Expense (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of detailed information about intangible assets [line items]
Total research and development expenses	€ (72,873)	€ (30,588)
Clinical Expenses
Disclosure of detailed information about intangible assets [line items]
Total research and development expenses	(44,256)	(21,026)
Non-clinical Expenses
Disclosure of detailed information about intangible assets [line items]
Total research and development expenses	(1,837)	(1,264)
Personnel Expense
Disclosure of detailed information about intangible assets [line items]
Total research and development expenses	(13,708)	(1,869)
Manufacturing Costs
Disclosure of detailed information about intangible assets [line items]
Total research and development expenses	(12,633)	(6,001)
Regulatory Expenses
Disclosure of detailed information about intangible assets [line items]
Total research and development expenses	(394)	(381)
Other R&D costs
Disclosure of detailed information about intangible assets [line items]
Total research and development expenses	€ (45)	€ (47)

Share-Based Payments - Additional information (Details)		1 Months Ended	6 Months Ended
Share-Based Payments - Additional information (Details)	Aug. 01, 2021	Jul. 31, 2021 EUR (€)	Jun. 30, 2023 EUR (€) shares € / shares	Jun. 30, 2023 EUR (€) shares € / shares $ / shares	Jun. 30, 2022 EUR (€)	Dec. 31, 2022 EUR (€) shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting percentage of share options granted	25.00%
Number of options, Granted \| shares			4,558,729
Number of options outstanding \| shares			13,966,164	13,966,164		11,146,861
Outstanding options, exercisable \| shares			4,189,605	4,189,605
Exercise price, granted \| $ / shares				$ 11.01
Exchange ratio					2.13
Weighted average remaining contractual life			9 years
Vesting period	4 years		4 years
Expected dividend rate			0.00%
Share based payment liabilities			€ 2,951,000	$ 2,951,000
Payments for share issue costs		€ 708,571
Liability for unvested Ordinary Shares			€ 192,000	$ 192,000
Business Combination Agreement \| Participating Optionholders
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Earnout shares \| shares			160,404	160,404
Ordinary Shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Par value per share \| € / shares			€ 0.12	$ 0.12
Ordinary shares vested \| shares			443,901
Long Term Incentive Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted average remaining contractual life			10 years
Vesting after One Year
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting percentage of share options granted			25.00%
Vesting in Equal Installments Over Next Following Three Years
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting percentage of share options granted	75.00%		75.00%
Share-based Payment Arrangement, Option
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share based payment expense recognized for equity settled option			€ 12,100,000		€ 300,000
Share based payment liabilities			2,800,000	$ 2,800,000		€ 100,000
Expense for the employer social security contributions			€ 1,100,000		€ 0.0

Earnings Per Share - Summary Of Weighted Average Number Of Ordinary Shares Outstanding For Basic And Diluted EPS (Details)	6 Months Ended
	Jun. 30, 2023 shares	Jun. 30, 2022 shares
Earnings Per Share [Abstract]
Shares for basic EPS of NewAmsterdam Pharma	81,846,438	36,258,312
Exchange ratio		2.13
Shares for diluted EPS of NewAmsterdam Pharma	81,846,438	40,443,670
As reported
Earnings Per Share [Abstract]
Shares for basic EPS of NewAmsterdam Pharma	81,846,438	17,016,872
Shares for diluted EPS of NewAmsterdam Pharma	81,846,438	18,981,158

Related Parties

6 Months Ended

Jun. 30, 2023

Disclosure Of Transactions Between Related Parties [Abstract]

Related Parties

Note 11 — Related Parties

During the six months ended June 30, 2023 and 2022 the Company did not have any material transactions with related parties.

Terms and conditions of transactions with related parties

Transactions with related parties, other than the remuneration of certain non-executive directors as disclosed below, are made on terms equivalent to those that prevail in arm’s length transactions. Outstanding balances at the year-end are unsecured and interest free and settlement generally occurs in cash. There have been no guarantees provided or received for any related party receivables or payables.

Compensation to Directors and Senior Managers of the Company

The Company’s compensation includes base salary, as well as short and long-term incentive schemes.

Key Management Personnel (“KMPs”) are those persons having authority and responsibility for planning, directing and controlling the activities of the Group, including the directors of the Company. KMPs include the Chief Executive Officer, Chief Financial Officer, Chief Science Officer, Chief Operating Officer, Chief Business Officer and Vice President of Research and Development. The following table sets forth the total compensation paid to KMPs during the six months ended June 30:


	2023		2022

Short-term employee benefits		2,198		1,257
Share-based payments		10,164		290
Total compensation paid to key management personnel		12,362		1,547

Additionally, certain non-executive directors of the Company who serve as representatives of the Company’s shareholders and as such, have of received cash remuneration from the Company during the six months ended June 30, 2023 and 2022 totaling €166 thousand and €39 thousand, respectively, and share-based payment expenses during the period totaling €241 thousand and €11 thousand, respectively.